Quantcast
Home > Quotes > OCUL
OCUL

Ocular Therapeutix, Inc. Common Stock (OCUL) Quote & Summary Data

$4.1
*  
0.04
0.99%
Get OCUL Alerts
*Delayed - data as of Mar. 19, 2019  -  Find a broker to begin trading OCUL now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    OCUL Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 4.26 / $ 4.07
Share Volume
566,544
50 Day Avg. Daily Volume
493,303
Previous Close
$ 4.06
52 Week High / Low
$ 8.2769 / $ 3.46
Market Cap
175,629,945
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
566,544
50 Day Avg. Daily Volume:
493,303

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.57

Trading Range

The current last sale of $4.10 is 18.50% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 4.26 $ 8.2769
 Low: $ 4.07 $ 3.46

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on the formulation, development and commercialization of innovative therapies for diseases and conditions of the eye using our proprietary, bioresorbable hydrogel platform technology. We use this technology to tailor duration and amount of delivery of a range of therapeutic agents of varying duration in our product candidates. We are pursuing three overall strategic goals: · To make prescription eye drops obsolete; · To make immediate release, back-of-the-eye injections obsolete; and · To extend our hydrogel platform technology for use beyond the eye to other areas of the body. We currently incorporate therapeutic agents that have previously received regulatory approval, including small molecules and proteins, into our hydrogel technology with the goal of providing local programmed-released delivery of drug to the eye.  ... More ...  



Risk Grade

Where does OCUL fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 4.18
Open Date:
Mar. 19, 2019
Close Price:
$ 4.10
Close Date:
Mar. 19, 2019


Consensus Recommendation

Analyst Info